Every material Form 8-K Compass Therapeutics, Inc. has filed with the SEC since July 01, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Compass Therapeutics reported a third-quarter 2026 net loss of $27.2 million, or $0.15 per share, up from $14.3 million, or $0.08 per share, a year earlier. Higher research and development and general and administrative spending drove the increase, and cash and marketable securities fell to $163 million, which the company says will fund operations into 2028.
Q3 2026 net loss was $27.2 million ($0.15 per share) versus $14.3 million ($0.08 per share) in Q3 2025.
Nine-month net loss was $70.6 million ($0.38 per share) versus $50.8 million ($0.34 per share) a year earlier.
Cash and marketable securities were $163 million at September 30, 2026, down from $209 million at December 31, 2025, with $48 million used in operating activities.
Compass Therapeutics said the FDA recommended it conduct a trial demonstrating a survival benefit before submitting a Biologics License Application for tovecimig in previously treated advanced biliary tract cancer. The company said it does not believe a new trial is warranted before submission and will keep engaging with the FDA, which means the timing and path to approval are now uncertain.
FDA recommended a trial demonstrating a survival benefit before a BLA submission for tovecimig
Phase 2/3 COMPANION-002 showed ORR of 18.0% vs. 5.3% with paclitaxel alone (p=0.0228)
Median progression-free survival was 4.7 vs. 2.6 months, hazard ratio 0.44 (p<0.0001)
Overall survival analyses did not reach statistical significance due to crossover
Compass Therapeutics reported second-quarter 2026 results, with a net loss of $25.2 million, up from $19.9 million a year earlier, as research and development and general and administrative expenses rose. Cash and marketable securities fell to $180 million at June 30, 2026, which the company says should fund operations into 2028, and it expects FDA feedback on tovecimig in the third quarter.
Q2 2026 net loss of $25.2 million, or $0.13 per share, versus $19.9 million, or $0.14 per share, in Q2 2025
R&D expenses of $19.6 million, up 19%, and G&A expenses of $7.4 million, up 59%, from the year-earlier quarter
Cash and marketable securities of $180 million at June 30, 2026, down from $209 million at December 31, 2025
Company expects FDA feedback on tovecimig in Q3 2026 and an ESMO oral presentation in October 2026
Compass Therapeutics furnished an updated corporate presentation dated July 2026 that includes data from its COMPANION-002 study of tovecimig plus paclitaxel in biliary tract cancer. The study met its primary endpoint of overall response rate (18.0% vs 5.3%) and showed a longer median progression-free survival (4.7 vs 2.6 months), but overall survival was not significantly different (8.9 vs 9.4 months) because of crossover.
Primary endpoint overall response rate was 18.0% for tovecimig plus paclitaxel vs 5.3% for paclitaxel alone (p=0.0228)
Median progression-free survival was 4.7 vs 2.6 months (HR=0.44, p<0.0001); median overall survival was 8.9 vs 9.4 months (HR=1.05, p=0.78)
Company plans an FDA meeting in Q3 2026 and a BLA filing in Q4 2026, with potential approval in 2027
Company reported $195 million in cash and marketable securities at Q1 2026, with runway into 2028
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Compass Therapeutics, Inc. filing is on SEC EDGAR ↗. 8-K briefs of other companies →